Core Points - Propanc Biopharma, Inc. is set to begin trading on Nasdaq under the symbol PPCB after pricing an underwritten public offering of 1,000,000 shares at $4.00 per share, expected to yield approximately $4 million in gross proceeds [1][2] - The offering is anticipated to close on August 18, 2025, and includes a 45-day option for the underwriter to purchase an additional 150,000 shares [2][3] - The company’s shares were previously quoted on the OTC Markets, Pink Tier, and will cease to be quoted as of August 14, 2025, with no action required from stockholders [3] Company Overview - Propanc Biopharma, Inc. is focused on developing novel cancer treatments aimed at preventing recurrence and metastasis of solid tumors, specifically targeting pancreatic, ovarian, and colorectal cancers [6][7] - The company’s therapy utilizes pancreatic proenzymes to target and eradicate cancer stem cells, leveraging the body's natural defense mechanisms against cancer [6][7]